Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 12/20 | 0.52 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7882826 | 0.89 | HCRTR2 (0.49) | HCRTR2HCRTR1 | |
| SCHEMBL3800868 | 0.88 | HCRTR2 (0.56) | HCRTR2HCRTR1MAPK1MAPTCYP1A2 | |
| SCHEMBL601125 | 0.86 | HCRTR2 (0.57) | HCRTR2HCRTR1MEN1KMT2A | |
| SCHEMBL7882881 | 0.76 | HCRTR2 (0.44) | HCRTR2HCRTR1 | |
| SCHEMBL601149 | 0.74 | HCRTR2 (0.48) | HCRTR2HCRTR1MCHR1 | |
| SCHEMBL30795354 | 0.74 | HCRTR2 (0.50) | HCRTR2HCRTR1MCHR1 | |
| SCHEMBL600284 | 0.74 | HCRTR2 (0.50) | HCRTR2HCRTR1MCHR1 | |
| SCHEMBL600265 | 0.72 | HCRTR2 (0.41) | HCRTR2MAPK1POLBTSHRLMNA | |
| SCHEMBL3584731 | 0.72 | GRM5 (0.68) | MAPK1POLBTSHRLMNAMEN1 | |
| SCHEMBL3584728 | 0.72 | GRM5 (0.68) | MAPK1POLBTSHRLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421370-A1 | 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS | Merck Sharp & Dohme Corp. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20120040998-A1 | 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS | MERCER SWATI P (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040998-A1 | 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS | GRM5, GRIK5, GRM2 | HCRTR2 102/4885HCRTR1 199/4885MAPK1 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.